SCHEDULE 13G/A: Wellington Management Discloses 4.6% Stake in Haemonetics

Wellington Management Group LLP and its affiliates reported a 4.6% beneficial ownership stake in Haemonetics Corporation as of June 30, 2025.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively reported beneficial ownership of 2,203,351 shares of Haemonetics Corporation's Common Stock.
• This represents 4.6% of the total outstanding shares of Haemonetics Corporation.
• The reporting entities hold shared voting power over 1,790,776 shares and shared dispositive power over 2,203,351 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Haemonetics Corporation.
• The filing is an Amendment No. 6 to a Schedule 13G, indicating a previous filing and an update to the ownership position.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates a significant institutional investor maintains a substantial stake, suggesting continued confidence in the company, without any negative disclosures.

Positives

• Continued significant institutional ownership by a major investment firm like Wellington Management Group LLP can be viewed as a positive signal of confidence in Haemonetics Corporation's long-term prospects.

Future Outlook

NA

Industry Context

This filing reflects a standard disclosure of institutional ownership, common among large asset managers. It does not provide specific insights into broader industry trends but indicates continued investment in the medical technology sector, where Haemonetics operates.

Stakeholder Impact

• Shareholders may view the continued significant stake by Wellington Management as a sign of institutional confidence in Haemonetics Corporation, potentially influencing market perception positively.

Key Dates

Recommendation

This Schedule 13G filing primarily provides an update on institutional ownership and does not contain financial performance data or strategic announcements that would warrant a strong buy or sell recommendation. The continued holding by a major investment firm like Wellington Management suggests a neutral to slightly positive outlook, supporting a 'hold' recommendation for existing investors.

Keywords

Haemonetics Corporation, Wellington Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser